154 related articles for article (PubMed ID: 11682689)
1. Prophylaxis of cytomegalovirus infection in renal transplantation.
Ostermann M; MacPhee I; Chang R
Nephrol Dial Transplant; 2001 Nov; 16(11):2276-9. PubMed ID: 11682689
[No Abstract] [Full Text] [Related]
2. The renal safety of high doses of valacyclovir for prevention of cytomegalovirus infection after renal transplantation.
Le Meur Y; Mons S; Moesch C; Leroux-Robert C
Nephrol Dial Transplant; 2000 Mar; 15(3):442. PubMed ID: 10692544
[No Abstract] [Full Text] [Related]
3. Prophylaxis of cytomegalovirus infection in renal transplantation: new data for an old problem.
Kuypers DR; Vanrenterghem YF
Nephrol Dial Transplant; 1999 Oct; 14(10):2304-8. PubMed ID: 10528649
[No Abstract] [Full Text] [Related]
4. Lowering immunosuppression is safe and effective to treat altered pattern of CMV infection in renal transplant recipients on valaciclovir prophylaxis.
Anglicheau D; Lautrette A; Scieux C; Thervet E; Martinez F; Flamant M; Morinet F; Legendre C
Transplant Proc; 2002 Nov; 34(7):2826-7. PubMed ID: 12431624
[No Abstract] [Full Text] [Related]
5. Successful use of oral valacyclovir in post-transplant cytomegalovirus infection in renal allograft recipients.
Himmelmann-Jud B; Wüthrich RP; Weinreich T; Binswanger U
Nephrol Dial Transplant; 1998 May; 13(5):1326-7. PubMed ID: 9623588
[No Abstract] [Full Text] [Related]
6. The efficacy and cost-effectiveness of valacyclovir in cytomegalovirus prevention in solid organ transplantation.
Reischig T; Kacer M
Expert Rev Pharmacoecon Outcomes Res; 2014 Dec; 14(6):771-9. PubMed ID: 25252996
[TBL] [Abstract][Full Text] [Related]
7. Randomized trial of pre-emptive or prophylactic valganciclovir therapy for prevention of cytomegalovirus infection in renal transplantation.
Santos RD; Brennan DC
J Am Soc Nephrol; 2012 Sep; 23(9):1446-8. PubMed ID: 22878958
[No Abstract] [Full Text] [Related]
8. The economic value of valacyclovir prophylaxis in transplantation.
Squifflet JP; Legendre C
J Infect Dis; 2002 Oct; 186 Suppl 1():S116-22. PubMed ID: 12353196
[TBL] [Abstract][Full Text] [Related]
9. Valacyclovir for the prevention of cytomegalovirus disease after renal transplantation. International Valacyclovir Cytomegalovirus Prophylaxis Transplantation Study Group.
Lowance D; Neumayer HH; Legendre CM; Squifflet JP; Kovarik J; Brennan PJ; Norman D; Mendez R; Keating MR; Coggon GL; Crisp A; Lee IC
N Engl J Med; 1999 May; 340(19):1462-70. PubMed ID: 10320384
[TBL] [Abstract][Full Text] [Related]
10. Valacyclovir for cytomegalovirus prophylaxis reduces the risk of acute renal allograft rejection.
Reischig T; Jindra P; Mares J; Cechura M; Svecová M; Hes O; Opatrný K; Treska V
Transplantation; 2005 Feb; 79(3):317-24. PubMed ID: 15699762
[TBL] [Abstract][Full Text] [Related]
11. Valaciclovir update.
Bell AR
Adv Exp Med Biol; 1999; 458():149-57. PubMed ID: 10549387
[No Abstract] [Full Text] [Related]
12. A randomized prospective controlled trial of oral ganciclovir versus oral valacyclovir for prophylaxis of cytomegalovirus disease after renal transplantation.
Reischig T; Opatrny K; Bouda M; Treska V; Jindra P; Svecova M
Transpl Int; 2002 Dec; 15(12):615-22. PubMed ID: 12478408
[TBL] [Abstract][Full Text] [Related]
13. Valacyclovir prevention of cytomegalovirus reactivation after heart transplantation: a randomized trial.
Egan JJ; Carroll KB; Yonan N; Woodcock A; Crisp A
J Heart Lung Transplant; 2002 Apr; 21(4):460-6. PubMed ID: 11927223
[TBL] [Abstract][Full Text] [Related]
14. Valacyclovir provides optimum acyclovir exposure for prevention of cytomegalovirus and related outcomes after organ transplantation.
Fiddian P; Sabin CA; Griffiths PD
J Infect Dis; 2002 Oct; 186 Suppl 1():S110-5. PubMed ID: 12353195
[TBL] [Abstract][Full Text] [Related]
15. Prophylaxis of human cytomegalovirus infection in renal transplant patients with valacyclovir and ganciclovir.
Zhang P; Wang W; Zhang L; Li SF; Guan LB; Dong LQ; Zhou S; Yu P
Acta Virol; 2013; 57(3):375-7. PubMed ID: 24020766
[No Abstract] [Full Text] [Related]
16. Cytomegalovirus prophylaxis in pediatric kidney transplantation: the Dutch experience.
Jongsma H; Bouts AH; Cornelissen EA; Beersma MF; Cransberg K
Pediatr Transplant; 2013 Sep; 17(6):510-7. PubMed ID: 23890076
[TBL] [Abstract][Full Text] [Related]
17. Ganciclovir-resistant cytomegalovirus.
Legendre C
Lancet; 2000 Oct; 356(9238):1356. PubMed ID: 11073050
[No Abstract] [Full Text] [Related]
18. Randomized comparison of oral valacyclovir and intravenous ganciclovir for prevention of cytomegalovirus disease after allogeneic bone marrow transplantation.
Winston DJ; Yeager AM; Chandrasekar PH; Snydman DR; Petersen FB; Territo MC;
Clin Infect Dis; 2003 Mar; 36(6):749-58. PubMed ID: 12627359
[TBL] [Abstract][Full Text] [Related]
19. Valganciclovir versus valaciclovir for prevention of alemtuzumab-induced cytomegalovirus reactivation: what are the implications for routine clinical practice?
Smolej L
Blood; 2008 Sep; 112(5):2167. PubMed ID: 18725576
[No Abstract] [Full Text] [Related]
20. Efficacy and safety of lowering immunosuppression to treat CMV infection in renal transplant recipients on valaciclovir prophylaxis: a pilot study.
Anglicheau D; Lautrette A; Scieux C; Flamant M; Morinet F; Legendre C
Nephrol Dial Transplant; 2003 Aug; 18(8):1654-6. PubMed ID: 12897109
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
